Skip to search formSkip to main contentSkip to account menu

BMS 200475

Known as: BMS-200475 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Deoxyguanosine
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Synthetic Study towards Entecavir
A synthetic design of Entecavir was described, and the intermediate, (S)-N-methoxy -3-((4-methoxybenzyl)oxy)-N-methylpent-4… 
2013
2013
Total synthesis of entecavir.
Entecavir (BMS-200475) was synthesized from 4-trimethylsilyl-3-butyn-2-one and acrolein. The key features of its preparation are… 
Review
2006
Review
2006
Entecavir for the treatment of chronic hepatitis B virus infection.
Review
2005
Review
2005
A review of entecavir in the treatment of chronic hepatitis B infection
ABSTRACT Background: Infection with the hepatitis B virus (HBV) affects two billion people worldwide, and an estimated 400… 
2002
2002
Synthesis of novel (2R,4R)- and (2S,4S)-iso dideoxynucleosides with exocyclic methylene as potential antiviral agents.
Highly Cited
1998
Highly Cited
1998
Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection
ABSTRACT Daily oral treatment with the cyclopentyl 2′-deoxyguanosine nucleoside BMS-200475 at doses ranging from 0.02 to 0.5 mg… 
1998
1998
BMS-200475 and Lobucavir Polymerases by the Triphosphates of In Vitro Inhibition of Hepadnavirus
Highly Cited
1997
Highly Cited
1997
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
BMS-200475 is a novel carbocyclic 2'-deoxyguanosine analog found to possess potent and selective anti-hepatitis B virus (anti-HBV… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)